Insmed Incorporated
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antiba…
Biotechnology
US, Bridgewater [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | 6.57 | -30.68 | -32.84 | |
| Graham Fair Price | 6.06 | 8.63 | 8.14 | |
| PEG | -6.71 | 0.37 | -0.39 | |
| Price/Book | 36.88 | -8.53 | -13.52 | |
| Price/Cash Flow | 37.72 | -21.02 | -33.75 | |
| Prices/Earnings | -4.70 | -6.31 | -6.03 | |
| Price/Sales | -2.01 | 52.54 | 53.62 | |
| Price/FCF | 37.72 | -21.02 | -33.75 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Somewhat Weak
Fundamentals
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | -3.54 | 0.75 | 0.78 | |
| Operating Margin | 2.12 | -2.08 | -2.13 | |
| ROA | 3.13 | -0.14 | -0.14 | |
| ROE | 0.56 | 0.34 | -39.71 | |
| ROIC | -0.21 | -0.18 | 11.21 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | 0.14 | < 0.005 | 2339.44 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | -0.21 | 0.12 | -43.52 | |
| EPS QOQ | -0.15 | 0.17 | 12.22 | |
| FCF QOQ | 0.04 | -0.42 | 838.81 | |
| Revenue QOQ | 0.06 | -0.10 | 67.51 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Balanced
Fundamentals
Leverage & Liquidity
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 406.24 | 398.83 | -1.82 | |
| Days Sales Outstanding (DSO) | 44.29 | 44.30 | 0.01 | |
| Inventory Turnover | 0.22 | 0.23 | 1.86 | |
| Debt/Capitalization | 1.38 | 1.54 | 11.32 | |
| Quick Ratio | 3.64 | 1.50 | -58.70 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | -2.29 | -3.13 | -36.59 | |
| Cash | 5.39 | 4.01 | -25.54 | |
| Capex | -0.01 | -0.03 | -111.98 | |
| Free Cash Flow | -0.92 | -1.27 | -38.43 | |
| Revenue | 0.58 | 0.51 | -12.01 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Bad
Fundamentals
Financial Health
06 - Financial Health ·
Weak